The year 2023 marked an exciting milestone for the medical community as the North American Spine Society (NASS) gathered in the vibrant city of Los Angeles, California. Among the many distinguished participants at this prestigious event, Doctech.live, a renowned Med-Tech Innovation Report and journalist company sponsored by Ghost Productions Inc., had the privilege of conducting an illuminating interview with representatives from Kuros Biosciences.
Kuros Biosciences, a Swiss-headquartered global innovation company with an impressive 150 years of combined research experience in the field of biologics for spinal fusion, took center stage at NASS 2023. Their mission? To alleviate the significant burden of spine-related pain, a condition that exacts a toll on individuals, workplaces, and healthcare systems alike. With nearly one in five spinal fusion surgeries resulting in non-union of spinal bones, Kuros Biosciences aimed to revolutionize spinal fusion through superior biologics. Here, we delve into the highlights of this captivating interview.
Kuros Biosciences’ Innovative Solutions
Katherine Sage, an esteemed orthopedic surgeon, and Joost DeBruijn, President of Innovation & Strategy at Kuros Biosciences, took the stage for the interview. The conversation began with an overview of Kuros Biosciences’ groundbreaking technologies – MagnetOs and Fibrin-PTH.
MagnetOs: A Bone Graft Like No Other
MagnetOs stands out as a bone graft of unparalleled distinction, thanks to its revolutionary NeedleGrip™ surface technology. This innovative feature enables the growth of bone even in soft tissues, promising more predictable fusion outcomes. MagnetOs is a synthetic calcium phosphate with a unique surface topography that stimulates the body to form bone on the material. Unlike conventional bone graft materials, MagnetOs offers a distinct advantage in promoting bone growth, making it a game-changer in the field of spinal fusion.
Fibrin-PTH: Pioneering Investigational Drug-Biologic Candidate
Fibrin-PTH, Kuros Biosciences’ latest innovation in the pipeline, represents a groundbreaking approach to spinal fusion. As the first investigational drug-biologic candidate for spinal fusion, Fibrin-PTH has the potential to transform the landscape of spinal surgery. With unique properties and applications, it holds the promise of being a true game-changer in the field.
Project Fusion – A Global Research Initiative
Kuros Biosciences firmly believes that advancing the quality and quantity of scientific research is the key to reducing the burden of spine-related surgeries, particularly in light of high non-union rates. To address this challenge, they introduced “Project Fusion,” a global research program that combines an unprecedented blend of scientific, pre-clinical, and clinical studies. This initiative reflects their commitment to evidence-based innovation and their dedication to improving patient outcomes.
NASS 2023 – The Premier Spinal Health Event
The North American Spine Society (NASS) conference is a pivotal event in the medical world, attracting stakeholders from various sectors, including medical device manufacturers, surgeons, medical marketers, and more. NASS provides a platform for renowned leaders in spine-related fields to engage in discussions, network, and collaborate on addressing the most pressing issues facing spine professionals today. In 2023, NASS convened in Los Angeles, the entertainment capital of the world, setting the stage for groundbreaking discussions and discoveries in the realm of spinal health.
As Doctech.live continues to fulfill its mission of delivering high-quality, accurate, and up-to-date coverage of health and medicine, interviews like the one with Kuros Biosciences serve as a testament to the exciting advancements and innovations that are shaping the future of healthcare.
In conclusion, Kuros Biosciences’ presence at NASS 2023 and their dedication to pioneering technologies like MagnetOs and Fibrin-PTH highlight the remarkable strides being made in the field of spinal fusion. With Project Fusion and their commitment to rigorous research, Kuros Biosciences is poised to make a significant impact on improving patient outcomes and redefining the future of spinal surgery.
